Dr. Maria Arcila, MD

• Molecular Genetic Pathology

• Hematopathology

• Anatomic & Clinical Pathology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Pittsburgh / Main Campus

  Medical School, 1997

• Prospective Blinded Study ofBRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders, 2014-10-16

• Bioinformatically-expanded next-generation sequencing analysis optimizes identification of therapeutically relevantMETcopy number alterations in >50,000 tumors, 2022-11-01

• Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated withKRASmutation, 2015-11-23

• EGFRExon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics, 2013-01-31

• Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and impacts clinical outcome, 2017-08-10

• DiverseBRCA1andBRCA2Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer, 2017-08-01

• AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants, 2015-02-24

• Prevalence, clinicopathologic associations and molecular spectrum ofERBB2(HER2) tyrosine kinase mutations in lung adenocarcinomas, 2012-07-03

• Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma withEGFRexon 20 insertions, 2021-03-08

• MAP2K1 (MEK1)mutations define a distinct subset of lung adenocarcinoma associated with smoking, 2014-10-28

• Accelerating discovery of functional mutant alleles in cancer, 2017-12-15

• AcquiredMETExon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor inEGFR-Mutated Lung Cancer, 2019-05-10

• Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma, 2019-10-21

• Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples, 2016-08-25

• Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large cell carcinoma, 2012-11-30

• The value of cell-free DNA for molecular pathology, 2018-03-12

• Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials, 2015-08-28

• High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden, 2019-04-26

• DNA Damage Response and Repair Gene Alterations Are Associated With Improved Survival In Patients With Platinum-Treated Advanced Urothelial Carcinoma, 2017-01-30

• Next generation sequencing of breast implant associated anaplastic large cell lymphomas reveals a novelSTAT3-JAK2fusion among other activating genetic alterations within theJAK-STATpathway, 2021-02-18

• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia, 2014-02-19

• Androgen Receptor Splicing Variant-7 in Breast Cancer: Clinical and Pathologic Correlations, 2021-09-30

• Activation of KRAS mediates resistance to targeted therapy in MET exon 14 mutant non-small cell lung cancer, 2018-10-23

• Genomic Differences Between "Primary” and "Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy, 2018-10-02

• The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation, 2020-08-24

• Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature, 2015-01-07

• Cancer therapy shapes the fitness landscape of clonal hematopoiesis, 2020-10-26

• Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making, 2017-05-31

• AcquiredALKandRETGene Fusions as Mechanisms of Resistance to Osimertinib inEGFR-Mutant Lung Cancers, 2018-09-04

• NCCN Work Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies, 2016-12-24

• Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C Mutant Non-Small Cell Lung Cancer, 2021-02-08

• The Genomic Landscape ofSMARCA4Alterations and Associations with Outcomes in Patients with Lung Cancer, 2020-07-24

• Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring anNTRKGene Fusion, 2018-07-23

• Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes, 2021-05-04

• ALKRearrangements Are Mutually Exclusive with Mutations inEGFRorKRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer, 2013-05-31

• AcquiredMETExon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer, 2019-05-10

• Genomic Alterations as Predictors of Survival Among Patients within a Combined Cohort with Clear Cell Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy, 2017-04-10

• HER2amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation, 2012-09-05

• Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status in Invasive Breast Carcinoma: A Focus on Group 4 Using the 2018 ASCO/CAP HER2 Testing Guideline, 2020-10-12

• AcquiredBRAFrearrangements induce secondary resistance to EGFR therapy inEGFR-mutated lung cancers, 2019-03-01

• Brief report: Screening for germlineEGFRT790M mutations through lung cancer genotyping, 2012-03-31

• Frequent somaticCDH1loss-of-function mutations in plasmacytoid-variant bladder cancer, 2016-02-22

• Bronchiolar Adenoma: Expansion of the Concept of Ciliated Muconodular Papillary Tumors with Proposal for Revised Terminology Based on Morphologic, Immunophenotypic and Genomic Analysis of 25 cases., 2021-04-17

• Invasive Mucinous Adenocarcinomas with Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling, 2021-04-08

• Mutant-RB1circulating tumor DNA in the blood of unilateral retinoblastoma patients: What happens during enucleation surgery: A pilot study, 2023-02-03

• Characterization and Impact ofTERTPromoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma, 2017-09-24

• Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms, 2019-11-25

• Response to ERBB3-Directed Targeted Therapy inNRG1-Rearranged Cancers, 2018-04-02

• Engraftment Kinetics after Transplantation of Double Unit Cord Blood Grafts Combined with Haplo-identical CD34+ Cells without Anti-thymocyte Globulin, 2020-06-18

• Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression ofERBB2(HER2), 2015-05-15

• Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma, 2019-03-22

• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay, 2011-01-19

• METexon 14-altered lung cancers and MET inhibitor resistance, 2020-11-10

• Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer, 2014-05-06

• New Strategies in Overcoming Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer, 2011-07-20

• Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer, 2020-01-07

• ConcurrentRB1andTP53alterations define a subset ofEGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes, 2019-06-19

• Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS, 2021-06-18

• EGFRExon 19 Insertions: A New Family of SensitizingEGFRMutations in Lung Adenocarcinoma, 2011-12-21

• Germline EGFR T790M mutation found in multiple members of a familial cohort, 2014-10-23

• Afatinib in patients with metastatic or recurrentHER2-mutant lung cancers: a retrospective international multicenter study, 2019-01-24

• Molecular Epidemiology ofIDH2Hotspot Mutations in Cancer and Immunohistochemical Detection of R172K, R172G and R172M Variants, 2020-10-02

• SCLEROSING EPITHELIOID MESENCHYMAL NEOPLASM OF THE PANCREAS A PROPOSED NEW ENTITY, 2019-08-05

• HER2amplification andHER2mutation are distinct molecular targets in lung cancers, 2015-12-24

• Lessons learned from routine, targeted assessment of liquid biopsies forEGFRT790M resistance mutation in patients withEGFRmutant lung cancers, 2019-07-26

• DNMT3A R882mutations promote anthracycline resistance in acute myeloid leukemia through impaired nucleosome remodeling, 2016-11-14

• KRAS Mutation is a Significant Prognostic Factor in Early Stage Lung Adenocarcinoma, 2016-08-26

• Clinical utility of next-generation sequencing-based ctDNA testing for common and novelALKfusions, 2021-07-17

• Genetic and epigenetic landscape of IDH-wildtype glioblastomas withFGFR3-TACC3fusions, 2020-11-09

• Resistance to Imatinib in Patients with Chronic Myelogenous Leukemia and the Splice Variant BCR-ABL135INS, 2016-08-12

• Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma, 2017-10-20

• Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novelALKfusions” [Lung Cancer 159 (2021) 66-73], 2021-10-06

• Clinical and in vivo Evidence thatEGFRS768I Mutant Lung Adenocarcinomas Are Sensitive to Erlotinib, 2015-11-18

• Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications, 2019-10-15

• Frequency and Outcomes of Brain Metastases in Patients WithHER2-Mutant Lung Cancers, 2019-08-30

• A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer, 2015-12-16

• Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies, 2017-03-23

• Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in "driver-negative” lung adenocarcinomas, 2015-01-07

• Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists, 2017-03-21

• Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection ofNTRKFusions, 2017-06-24

• HER2-mediated internalization of cytotoxic agents inERBB2amplified or mutant lung cancers, 2020-03-25

• JAK2/PD-L1/PD-L2(9p24.1) Amplifications in Renal Cell Carcinomas with Sarcomatoid Transformation: Implications for Clinical Management, 2019-04-17

• Feasibility of Endobronchial Ultrasound Transbronchial Needle Aspiration for Massively Parallel Next-Generation Sequencing in Thoracic Cancer Patients, 2018-03-07

• Prognostic Impact of RAS pathway mutations in Patients with Myelofibrosis, 2019-10-18

• Genetic basis for iMCD-TAFRO, 2020-02-12

• Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach, 2019-08-30

• Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack ofEGFR/KRAS and presence ofPIK3CA/AKT1mutations, 2012-01-06

• Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma, 2016-07-16

• ERBB2Amplification Status in 67 Salivary Duct Carcinomas Assessed by Immunohistochemistry, Fluorescencein situHybridization and Targeted Exome Sequencing, 2021-12-28

• P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy, 2020-03-05

• Characteristics of Lung Cancers HarboringNRASMutations, 2013-03-20

• Acquired resistance to IDH inhibition throughtransorcisdimer-interface mutations, 2018-06-27

• Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF, 2015-12-11

• TP53Combined Phenotype Score Is Associated with the Clinical Outcome ofTP53-Mutated Myelodysplastic Syndromes, 2021-11-02

• Impact of concurrentPIK3CAmutations on response to EGFR tyrosine kinase inhibition inEGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas, 2016-02-07

• TFEBExpression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations, 2019-06-01